Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Court Places No Restrictions on Generic Lovenox

By Pharmaceutical Processing | July 27, 2010

CAMBRIDGE, Mass. (AP) — Biotechnology company Momenta Pharmaceuticals Inc. said today a federal court placed no restrictions on the sale of a generic version of Sanofi-Aventis SA’s Lovenox, an injected drug that prevents blood clots.

Momenta, which is based in Cambridge, Mass., said Sanofi has filed a lawsuit that asked, among other things, for a temporary restraining order and preliminary injunction directing the Food and Drug Administration to suspend its approval of the generic, known by its chemical name enoxaparin.

The U.S. District Court for the District of Columbia held a status conference Monday and scheduled a hearing for Aug. 17.

Last week, Momenta said the FDA had approved the generic, which it developed under a collaboration agreement with Sandoz, the generics business of Swiss drugmaker Novartis AG.

Enoxaparin can prevent blood clots in deep veins, as in the thigh or lower leg, which can break free and cause a fatal blockage in a lung artery. At least 100,000 such clots occur in the U.S. each year. They are the third-most common cause of death in hospitalized patients.

The drug can also be used to prevent blood clots in patients suffering a heart attack or chest pain, or those confined to bed.

Israel’s Teva Pharmaceutical Industries Ltd. also is developing a generic version of Lovenox.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE